期刊文献+

药代动力学/药效动力学模型在降糖药物评价中的应用 被引量:1

The Application of Pharmacokinetic/pharmacoydnamic Models in Hypoglycemic Drug Researh
下载PDF
导出
摘要 本文通过检索国外相关文献,对采用PK/PD方法对降糖药物及其制剂进行评价的研究进行归纳整理。以介绍药代动力学/药效动力学(pharmacokinetic/pharmacodynamic,PK/PD)模型在降糖药物及其制剂评价中的应用。检索结果表明血糖和胰岛素的相关性是PK/PD模型中的重点部分,PK/PD模型能够评价不同制剂或给药方式下的降糖效果。PK/PD模型是降糖药物及其制剂研究中一种较好的评价方法。 The application of pharmacokinetic/pharmacoydnamic(PK/PD) models in the research process of hypoglycemic drug was introduced. The PK/PD methods used to evaluate hypoglycemic agents and their relevant preparations were collected from literatures and were analyzed. The correlation between blood glucose concentration and insulin level is the most important part in the PK/PD model. PK/PD model can be used to evaluate blood glucose-lowering effects of different formulations of hypoglycemic drugs. PK/PD model is a better methodfor hypoglycemic agent investigation.
出处 《药品评价》 CAS 2014年第10期14-18,26,共6页 Drug Evaluation
基金 "药物管理平台"子课题 国家科技部"脑血管病创新药物临床评价技术平台"重大专项基金 编号:2008ZX09312-008
关键词 药物动力学 药效动力学 降糖药物 胰岛素 Pharmacokinetic/pharmacoydnamic Hypoglycemic Drugs Insulin
  • 相关文献

参考文献2

二级参考文献25

  • 1Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104: 787-94.
  • 2BarnettAH. New treatments in type 2 diabetes:a focus on the incretin-based therapies. Clin Endocrinol (Oxf) 2009; 70: 343-53.
  • 3Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003; 26: 2929-40.
  • 4Parkes DG, Jodka C, Smith P, Nayak S, Rinehart L, Gingerich R, et al. Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon-like peptide-1. Drug Develop Res 2001; 53: 260-7.
  • 5Zander M, Madsbad S, Madsen JL, Hoist JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359: 824-30.
  • 6Parkes DG, Pittner R, Jodka C, Smith P, YoungA. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 2001; 50 583-9.
  • 7Stoffers DA, Kieffer TJ, Hussain MA, Drucker DJ, Bonner-Weir S, Habener JF, et al. Insulinotropic glucagon-like peptide-1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 2000; 49: 741-8.
  • 8Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)- amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells, J Biol Chem 1993; 268: 19650-5.
  • 9Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, et al. Glucose-lowering and insulin-sensitizing actions of exendin-4-studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 1999; 48: 1026-34.
  • 10Mager DE, Abernethy DR, Egan JM, Elahi D. Exendin-4 pharmacodynamics: insights from the hyperglycemic clamp technique. J Pharmacol Exp Ther 2004; 311: 830-5.

共引文献14

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部